Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Avastin can prolong the lives of women with advanced cervical cancer

New data showing cancer treatment Avastin (bevacizumab) can extend the lives of women with advanced cervical cancer compared to chemotherapy alone has been published in the New England Journal of Medicine.

21 Feb 2014

Matching the right tumor with the right drug

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

19 Feb 2014

A non-invasive method developed to fight heart disease

Clemson University researchers have developed nanoparticles that can deliver drugs targeting damaged arteries, a non-invasive method to fight heart disease.

18 Feb 2014

Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease demonstrates superior results

Four-year results of the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease continue to demonstrate consistent, superior results when compared to bare metal stents (BMS) and percutaneous transluminal angioplasty (PTA) in terms of primary patency, restenosis reduction and revascularization rates.

From COOK MEDICAL INC. 14 Feb 2014

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.

10 Feb 2014

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.

30 Jan 2014

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Researchers test promising new breast cancer drugs

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

14 Dec 2013

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Results from NeoALTTO trial to be presented at 2013 San Antonio Breast Cancer Symposium

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.

12 Dec 2013

Paclitaxel News and Research

Further Reading

Avastin can prolong the lives of women with advanced cervical cancer

Matching the right tumor with the right drug

A non-invasive method developed to fight heart disease

Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease demonstrates superior results

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Sorrento Therapeutics acquires Concortis Biosystems

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Researchers test promising new breast cancer drugs

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

Results from NeoALTTO trial to be presented at 2013 San Antonio Breast Cancer Symposium

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

Pemetrexed, paclitaxel regimens equally effective in NSCLC

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News